Global C-Reactive Protein Testing Market By Assay Type (Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay, Others) By Detection Range (hs-CRP, Conventional CRP, cCRP) By Disease Area (Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus, Others) Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2025-2034

Report Overview

Global C-Reactive Protein Testing Market size is expected to be worth around US$ 7.1 Billion by 2034 from US$ 5.1 Billion in 2024, growing at a CAGR of 3.4% during the forecast period from 2025 to 2034. In 2024, North America led the market, achieving over 32.2% share with a revenue of US$ 1.6 Billion.

The application of C-reactive protein (CRP) testing has been evaluated as a robust indicator of inflammatory activity across clinical environments. Serum or plasma specimens are subjected to immunoturbidimetric or high-sensitivity assays, which now permit the quantification of CRP down to concentrations of 0.3 mg/L. Such sensitivity enables the early detection of low-grade inflammation associated with cardiovascular risk, as well as acute infectious processes.

Turnaround times for CRP determinations have been reduced to under one hour in accredited laboratories through the deployment of automated analyzers. Test outcomes are classified according to established thresholds: values lower than 3 mg/L denote minimal risk, readings between 3 mg/L and 10 mg/L indicate moderate inflammatory activity, and measurements exceeding 10 mg/L signify pronounced inflammation. These stratifications support evidence-based clinical decision making, facilitating therapy adjustments and prognostic assessments.

Recent advances in point-of-care CRP platforms are anticipated to broaden accessibility, particularly in outpatient clinics and remote settings. The implementation of CRP testing within routine diagnostic panels has been associated with improved patient management, optimized treatment pathways, and reduced healthcare expenditures. Overall, the integration of high-performance CRP assays is projected to reinforce the precision and efficiency of inflammatory disease monitoring in diverse healthcare contexts.

Key Takeaways

• Market Size: Global C-Reactive Protein Testing Market size is expected to be worth around US$ 7.1 Billion by 2034 from US$ 5.1 Billion in 2024.
• Market Growth: The market growing at a CAGR of 3.4% during the forecast period from 2025 to 2034.
• Assay Type Analysis: In 2024, the immunoturbidimetric assay segment dominated with a 29.3% share of total market revenue.
• Detection Range Analysis: In 2024, the hs-CRP segment dominated with a 42.5% share of total market revenue.
• End-Use Analysis: In 2024, the cardiovascular diseases segment dominated with a 28.3% share of total market revenue.
• Regional Analysis: In 2024, North America led the market, achieving over 32.2% share with a revenue of US$ 1.6 Billion.

Assay Type Analysis

The C-reactive protein (CRP) testing market can be segmented by assay type into immunoturbidimetric assays, enzyme-linked immunosorbent assays (ELISA), chemiluminescence immunoassays, and other methods.

In 2024, the immunoturbidimetric assay segment dominated with a 29.3% share of total market revenue. This dominance can be attributed to the rapid turnaround time and high throughput capacity offered by automated immunoturbidimetric platforms, which support timely clinical decision-making and meet the demands of high-volume laboratories.

ELISA-based tests are recognized for their sensitivity and specificity, particularly in research settings, and accounted for a significant portion of the market. Chemiluminescence immunoassays have been increasingly adopted by diagnostic centers due to their enhanced signal detection and lower limit of detection, thereby supporting early detection of inflammatory conditions.

Other assay types, including high-sensitivity assays and point-of-care formats, contributed to the remaining market share by providing flexibility and accessibility in outpatient and remote settings. The diverse assay landscape can be attributed to differing clinical requirements, laboratory capabilities, and regional preferences.

Detection Range Analysis

The C-reactive protein (CRP) testing market is segmented by detection range into high-sensitivity CRP (hs-CRP), conventional CRP, and cardiac-specific CRP (cCRP) assays. In 2024, the hs-CRP segment dominated with a 42.5% share of total market revenue, owing to its ability to detect low-grade inflammation and predict cardiovascular risk with greater precision.

Conventional CRP assays held a substantial portion of the market, driven by their widespread use in general inflammation screening and cost-effectiveness in routine clinical laboratories. The cCRP segment gained traction in cardiology settings, where its intermediate sensitivity supports monitoring of acute cardiac events.

Selection among these detection ranges is influenced by clinical application, laboratory infrastructure, and regional diagnostic guidelines. For instance, hs-CRP tests are favored in preventive cardiology programs, while conventional CRP remains the standard in infection and autoimmune disease management. The diverse detection range offerings enable tailored diagnostic strategies across disease areas, ensuring that clinicians can balance sensitivity requirements with throughput and budget considerations.

Cardiovascular Diseases Analysis

The C-reactive protein (CRP) testing market is segmented by disease area into cardiovascular diseases, cancer, rheumatoid arthritis, inflammatory bowel disease, endometriosis, lupus, and others. In 2024, the cardiovascular diseases segment dominated with a 28.3 % share of total market revenue. This leadership can be attributed to the widespread adoption of high-sensitivity CRP assays in preventive cardiology programs, where precise risk stratification is critical.

Cancer applications accounted for a significant portion of the market as clinicians increasingly rely on CRP levels to monitor tumor associated inflammation and treatment response. Rheumatoid arthritis and inflammatory bowel disease segments held substantial shares, driven by routine use of CRP measurements to assess disease activity and guide biologic therapy adjustments.

The endometriosis and lupus segments have shown steady growth owing to the role of CRP as an adjunctive marker in complex autoimmune and gynecological conditions. The “others” category, encompassing infections, metabolic disorders, and postoperative monitoring, contributed the remaining share by providing flexible diagnostic options across diverse clinical settings. This segmentation reflects the varied clinical utility of CRP testing and the importance of tailored assay selection.

Key Market Segments

By Assay Type

• Immunoturbidimetric Assay
• ELISA
• Chemiluminescence Immunoassay
• Others

By Detection Range

• hs-CRP
• Conventional CRP
• cCRP

By Disease Area

• Cardiovascular Diseases
• Cancer
• Rheumatoid Arthritis
• Inflammatory Bowel Disease
• Endometriosis
• Lupus
• Others

Driver

The primary driver of the C-Reactive Protein (CRP) testing market is the rising global burden of cardiovascular and inflammatory diseases. In 2019, cardiovascular diseases (CVDs) accounted for 17.9 million deaths, representing 32 % of all global fatalities. As CRP is a sensitive biomarker for inflammation and cardiovascular risk stratification, demand for quantitative and high-sensitivity assays has grown.

Additionally, the increasing prevalence of chronic conditions such as rheumatoid arthritis and inflammatory bowel disease drives routine monitoring. Governments and health systems worldwide have incorporated CRP measurement into guidelines for risk assessment and monitoring of therapeutic response, further supporting market expansion.

Trend

A notable trend is the shift toward point-of-care (POC) and high-sensitivity CRP (hs-CRP) assays. Immunoturbidimetric systems like the QuikRead™ go CRP test have received FDA clearance for in-vitro quantitative determination of CRP in whole blood and plasma, enabling rapid clinical laboratory use.

Concurrently, lateral-flow POC platforms (e.g., FebriDx®) provide qualitative CRP detection from fingerstick blood, facilitating decentralized testing in urgent care settings. These innovations reduce turnaround time from hours to minutes, supporting early risk stratification and treatment decisions.

Restraint

A key restraint is CRP’s non-specificity as an acute-phase reactant. While CRP levels rise dramatically during inflammation, they cannot distinguish among infection, trauma, or chronic inflammatory disorders. This lack of specificity can lead to false positives and limit clinical utility when used in isolation.

Moreover, professional guidelines caution against employing hs-CRP as a standalone screening tool for average-risk, asymptomatic individuals. Consequently, clinicians often combine CRP results with other biomarkers and imaging studies, which may restrict standalone market growth.

Opportunity

Significant opportunity exists in low- and middle-income countries (LMICs), where over 75 % of CVD deaths occur. Expansion of primary healthcare infrastructure and government-led noncommunicable disease (NCD) screening initiatives can drive uptake of affordable CRP testing, particularly POC formats.

Furthermore, integration of CRP measurement into national screening programs for rheumatoid arthritis and other inflammatory disorders offers additional volume growth. With increasing health budgets and emphasis on early intervention, market players can collaborate with public health agencies to deploy portable, low-cost CRP assays in community settings.

Regional Analysis

In 2024, North America held a dominant market position, capturing more than a 32.2% share and holds US$ 1.6 Billion market value for the year. This dominance can be attributed to several factors. The prevalence of chronic pain in U.S. adults was 24.3% in 2023, driving demand for inflammatory markers. Diagnosed arthritis affected 18.9% of adults in 2022, further supporting test uptake. High cardiovascular disease costs in the U.S.an estimated US$ 129.3 billion in 2020–2021—have encouraged early risk assessment through hs-CRP assays.

In Europe, a significant share was held by Western markets. Screening guidelines were updated to include hs-CRP for cardiovascular risk stratification. Public health agencies promoted routine CRP testing. Government reimbursement policies were favorable. As a result, moderate growth was recorded. The share reached nearly one quarter of the global market.

The Asia Pacific region registered the fastest expansion. Rising healthcare expenditure and growing diagnostic infrastructure supported market uptake. In 2020, an estimated 523 million people had some form of cardiovascular disease, increasing the need for inflammatory biomarkers. National health programs also encouraged early detection.

Latin America and the Middle East & Africa collectively accounted for the remaining share. Emerging healthcare systems adopted CRP testing for infection management and chronic disease monitoring. Cost effective point-of-care platforms gained traction. Investments in laboratory capacity were noted.

Key Regions and Countries

North America

• US
• Canada

Europe

• Germany
• France
• The UK
• Spain
• Italy
• Russia
• Netherland
• Rest of Europe

Asia Pacific

• China
• Japan
• South Korea
• India
• Australia
• New Zealand
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE
• Rest of MEA

Key Players Analysis

In the C-Reactive Protein testing market, key participants are characterized by robust product portfolios and broad geographic footprints. Innovative assay technologies are continuously introduced to enhance sensitivity and throughput. Strategic collaborations with diagnostic laboratories are pursued to expand service offerings.

Investment in automated analyzer platforms is prioritized to reduce turnaround times and costs. Research and development expenditures are allocated to novel detection chemistries and point-of-care platforms. Regulatory compliance and quality certifications are maintained to ensure market access and customer confidence.

Distribution networks are optimized through partnerships with healthcare distributors. Pricing strategies are designed to balance affordability with profit margins. Market competitiveness is driven by technological innovation, service integration, and global reach. Aftermarket services are ensured to maintain customer loyalty.

Market Key Players

• Thermo Fisher Scientific, Inc.
• F. Hoffmann-La Roche Ltd.
• Danaher
• Quest Diagnostics
• Siemens Healthineers AG
• Abbott
• Merck KGaAA
• Zoetis
• Ortho Clinical Diagnostics
• Getein Biotech, Inc.
• HORIBA, Ltd

Recent Developments

• Thermo Fisher Scientific: In January 2023, The Binding Site Group was acquired for £2.25 billion (US$ 2.6 billion). This broadened Thermo Fisher’s Specialty Diagnostics segment to include acute-phase protein assays such as CRP and added US$ 0.07 to adjusted EPS in the first year.
• F. Hoffmann-La Roche Ltd.: In April 2025, the Diagnostics Division grew by 6 percent on a constant-exchange-rate basis, led by immunodiagnostics and clinical chemistry tests (including CRP). Investments in automated, high-throughput platforms bolstered high-sensitivity biomarker measurement.
• Danaher Corporation: On July 17, 2024, two Diagnostics Centers of Innovation were launched—including a CLIA-CAP lab in Newcastle, UK—to accelerate immunoassay R&D for acute-phase proteins like CRP and shorten development timelines for next-generation tests.
• Quest Diagnostics: On June 11, 2024, PathAI Diagnostics’ lab assets were acquired, integrating AI-driven host-response and protein assays (including CRP algorithms) into Quest’s network to enhance inflammatory biomarker analytics and clinical decision support.

Report Scope